| Year |
Citation |
Score |
| 2015 |
Wang M, Crosby A, Hastie E, Samulski JJ, McPhee S, Joshua G, Samulski RJ, Li C. Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Therapy. PMID 26125606 DOI: 10.1038/Gt.2015.69 |
0.301 |
|
| 2015 |
Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Human Gene Therapy. 26: 69-81. PMID 25419787 DOI: 10.1089/Hum.2014.106 |
0.362 |
|
| 2013 |
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, ... ... Samulski J, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4 |
0.47 |
|
| 2012 |
Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 443-55. PMID 22068425 DOI: 10.1038/Mt.2011.237 |
0.467 |
|
| 2011 |
Kantor B, Bayer M, Ma H, Samulski J, Li C, McCown T, Kafri T. Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 547-56. PMID 21157436 DOI: 10.1038/Mt.2010.277 |
0.36 |
|
| 2010 |
Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, ... Samulski J, et al. Dystrophin immunity in Duchenne's muscular dystrophy. The New England Journal of Medicine. 363: 1429-37. PMID 20925545 DOI: 10.1056/Nejmoa1000228 |
0.445 |
|
| 2003 |
Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D, Chérel Y, Chenuaud P, Samulski J, Moullier P, Rolling F. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 774-81. PMID 12788651 DOI: 10.1016/S1525-0016(03)00098-4 |
0.367 |
|
| 2002 |
Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang DJ, Shera D, Hurh P, Rupin J, Saslow E, Goldfarb O, Goldberg M, Larijani G, Sharrar W, ... ... Samulski J, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Human Gene Therapy. 13: 1391-412. PMID 12162821 DOI: 10.1089/104303402760128612 |
0.407 |
|
| Show low-probability matches. |